Laser photocoagulation, given early in the course of the disease, is highly effective at preventing visual deterioration?-6 Screening has been shown to be effective 7 -9 in detecting sight-threatening diabetic eye disease (STED) at justifiable costS.1O-13 Computerised general practice and district diabetes registers are being developed for easier identification of target populations,14 and screening programmes have now been instituted in a number of locations in the UK.9,1 5 The St Vincent Declaration in 1990 set targets for diabetes care including the reduction of blindness by one-third. 16 To demonstrate that such a target has been met in the future a measure of current baseline prevalence is required. Population-based data from the UK are restricted to a single study in an English town in 1988, 1 7 ,18 with data from other settings and other countries also available. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] The Liverpool Diabetic Eye Study (LDES) was established in 1991 to investigate screening for STED. In this report we present the profile of diabetes-related eye disease in a cohort of diabetic patients in inner city Liverpool to provide a baseline estimate of prevalence prior to the introduction of systematic screening.
Methods
As part of a systematic community-based screening programme all adult diabetic patients attending four inner city general practices, including those under the care of the hospital eye service, were identified from computerised practice registers. Underprivileged area scores (Jarman scores) based on the 1991 census, averaged for the electoral wards serving each practice, were used as an index of the potential workload or pressure on the services of the general practitioners in the study.29 Ethnic mix by electoral ward was recorded.
Patients were invited to attend for slit-lamp biomicr.oscopy and colour fundus photography. Slit-lamp biomicroscopy with 90 and 60 dioptre indirect lenses was performed in a hospital based clinic by a single consultant specialist in medical retinal disease (S.P.H.). Photography was performed in the general practice centre using a Canon CR4-45NM camera, tropicamide 1%, three overlapping non-stereoscopic 45° fields and 35 mm transparencies as previously reported.9 Data on demography and management of diabetes were obtained by questionnaire. Type I insulin-dependent diabetes was defined as age at onset < 30 years and/or definite insulin dependence (for example a single episode of ketoacidosis). Type II non insulin-dependent diabetes was defined as age at diagnosis � 30 years in the absence of insulin dependence. Type II patients who required insulin subsequent to diagnosis were termed insulin-requiring (IR) and those who did not were termed non-insulin requiring (NIR). Visual acuity was measured using a Snellen chart at 6 m with each eye separately, unaided, with distance spectacles and with pinhole, and best acuity was recorded for each eye. An acuity of 0% 6/24 in the better eye was taken as an indicator of significant visual disability, as utilised by others.
IS
Modified Wisconsin grading in the LDES for retinopathy, macular exudates and macular oedema has been described previously9 and is presented here in summary in Tables 1-3 . Levels of disease for each patient are given according to the worse eye. STED requiring referral to an ophthalmologist was defined as any of the In the photography group, 9 of 31 patients were ungradable for retinopathy and maculopathy due to media opacity. Two patients who were ungradable for retinopathy were gradable for maculopathy. A further 2 patients in the biomicroscopy group were ungradable for maculopathy but gradable for retinopathy.
The prevalence of retinopathy categorised by type of diabetes management is presented in Table 4 . Data for maculopathy are separated into gradings by macular exudate (Table 5 ) and macular oedema (Table 6 , grading of biomicroscopy group only). Cumulative data are summarised in Table 7 .
Data on visual function existed in 358 patients, including a known patient registered blind due to myopic degeneration who refused further examination. In the remaining 357 patients visual acuity (VA) in both eyes was 6/9 or better in 72% and 6/24 or better in 92%. ID, insulin-dependent; IR, insulin-requiring; NIR, non-insulin-requiring. Our estimate of baseline prevalence may be an underestimate. The attendance rate at the hospital clinic for biomicroscopy was over 80%, but in order to increase the sample size we added a group of patients who were not prepared to attend hospital and who only had photography. Obviously no measure for CSMO is possible in the photography-only group. The sensitivity of the photographic protocol used in this study has been previously reported by us as 89%9 and by others as 81 %, 8 and so a small number of cases may have been missed. In addition, 11 patients in the photography group were ungradable, increasing the possibility of underestimation.
Our point prevalence of 12.4/1000 is similar to previous studies: Reenders et aZ. 14.5/1000,28 Melton Mowbray 10.9/1000,1 7 ,18 WESDR 9.7/1000.32 Our study used a similar case acquisition to previous studies, but may have been incomplete as evidenced by a recently developed diabetes register in Scotland which has reported a prevalence of diabetes of 19.4/1000?3 General practice diabetes registers can also miss up to 18% of known diabetics.33 Liverpool has a low proportion of ethnic minority groups (overall 96.23% of the population are white), and in particular a low proportion of Asian persons, which may explain our lower prevalence of diabetes.
Other researchers have measured prevalence in selected groups. Reenders et aZ?8 reported a prevalence of any retinopathy of only 14% in a well-defined Dutch population. Their low estimate was probably due to poor sensitivity of direct ophthalmoscopy by general practitioners and a compliance rate of only 76%. Other groups have found higher prevalences. Kristinsson et al. 24 performed biomicroscopy on 90% of all type I diabetics in Iceland and found retinopathy in 52% and proliferative retinopathy in 13%. They also reported any retinopathy in 41%, proliferative retinopathy in 7% and CSMO in 10% of 245 patients (one-fifth of the total population) of type II diabetics in Iceland?S Agardh et aZ?6,2 7 reported retinopathy in 51.8% of diabetics attending a hospital service in Sweden, and Grey et al. 22 found retinopathy in 43.4% of insulin-dependent and 20.1% of non-insulin-dependent diabetics attending a hospital diabetic clinic in Bristol in 1981. In a retrospective cross-sectional study of insulin-treated patients in Denmark, Sj0lie23 reported an overall prevalence of any retinopathy of 41 %. However, data on up to one-third of patients were missing and examinations had been carried out over a 5-year period.
More direct comparison of the findings from our study is possible with two population studies: the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) in the USA in 1980-219-22 and the Melton Mowbray (MM) study from the UK in 1987. 1 7 ,18 In the WESDR a weighted stratification was used to select a sample of 1370 from 5431 diabetics identified from health records whose age at onset was over 30 years, while all younger-onset diabetics were included. The proportion Table 7 . Clinically relevant frequencies of retinopathy and maculopathy in the worse eye by disease category Our study confirms previous reports that the requirement for insulin in older-onset diabetics confers an especially high risk for the development of eye disease. Numbers in our study are small, but the highest prevalences of preproliferative disease (15.0%) and CSMO (16.2%) were found in this group. Similarly, the WESDR found the highest levels of preproliferative disease in their insulin-requiring older-onset group, although proliferative disease was higher in the younger onset group. Of their older-onset insulin-requiring patients, 15.2% had macular oedema compared with only 3.7% in the non-insulin-requiring group. The higher levels of retinopathy in the insulin-requiring type II group are probably due to prolonged exposure to hyperglycaemia and possibly delay in the initiation of insulin treatment. Targeting such high-risk groups with increased health resources is essential.
Both the WESDR and the LDES found higher prevalences of CSMO in the insulin groups (combining type I and type II IR: WESDR 12.8%, LDES 8.6%) compared with the non-insulin-requiring type II group (WESDR 3.7%, LDES 5.7%), refuting the commonly held belief that maculopathy is commoner in type II diabetics and retinopathy commoner in type 1.36 In the MM study a VA of 6/60 or less occurred in 4.0% overall (1.5% of insulin-taking patients and 6.0% of type II diabetics), although in the latter group the cause for the poor VA is not stated. In type I patients the prevalence of VA in the better eye of 6/60 or worse was 3.6% in the WESDR3 7 and 1.0% in Iceland/4 and in type II was 1.6% in the WESDR and 1.6% in Iceland? 5 In our population only 3 (0.8%) patients had a VA in the better eye of 6/60 or worse, none due to diabetic eye disease. Significant visual morbidity due to diabetic eye disease was found in 7 eyes of 4 patients. Overall rates of blindness and partial sight1 appear to continue unchanged although individual trends in blindness are harder to detect because of small numbers affected in each population studied.
In this report we have provided current prevalence rates for diabetic eye disease and visual disability in an inner city population in the UK. When extrapolated to entire populations in geographically defined areas, such figures allow for the costing and purchasing of screening services, audit of the screening cover of the target population and a baseline against which to measure St Vincent Declaration targets.
